Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback